- Home
- BMRN vs WYNN Comparison
BMRN vs WYNN Comparison
Compare BMRN & WYNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- WYNN
- Stock Information
- Founded
- BMRN 1996
- WYNN 2002
- Country
- BMRN United States
- WYNN United States
- Employees
- BMRN N/A
- WYNN N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- WYNN Hotels/Resorts
- Sector
- BMRN Health Care
- WYNN Consumer Discretionary
- Exchange
- BMRN Nasdaq
- WYNN Nasdaq
- Market Cap
- BMRN 11.3B
- WYNN 11.6B
- IPO Year
- BMRN 1999
- WYNN 2002
- Fundamental
- Price
- BMRN $57.54
- WYNN $109.45
- Analyst Decision
- BMRN Buy
- WYNN Buy
- Analyst Count
- BMRN 23
- WYNN 13
- Target Price
- BMRN $93.14
- WYNN $119.38
- AVG Volume (30 Days)
- BMRN 2.5M
- WYNN 1.8M
- Earning Date
- BMRN 08-04-2025
- WYNN 08-07-2025
- Dividend Yield
- BMRN N/A
- WYNN 0.91%
- EPS Growth
- BMRN 154.69
- WYNN N/A
- EPS
- BMRN 3.40
- WYNN 3.40
- Revenue
- BMRN $3,063,608,000.00
- WYNN $6,970,314,000.00
- Revenue This Year
- BMRN $12.34
- WYNN N/A
- Revenue Next Year
- BMRN $10.01
- WYNN $3.20
- P/E Ratio
- BMRN $16.93
- WYNN $32.22
- Revenue Growth
- BMRN 18.36
- WYNN N/A
- 52 Week Low
- BMRN $52.93
- WYNN $65.25
- 52 Week High
- BMRN $94.85
- WYNN $112.57
- Technical
- Relative Strength Index (RSI)
- BMRN 47.03
- WYNN 56.42
- Support Level
- BMRN $56.45
- WYNN $102.24
- Resistance Level
- BMRN $58.62
- WYNN $112.57
- Average True Range (ATR)
- BMRN 1.95
- WYNN 2.83
- MACD
- BMRN -0.25
- WYNN -0.26
- Stochastic Oscillator
- BMRN 15.51
- WYNN 69.80
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About WYNN Wynn Resorts Limited Common stock
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and the US, respectively. In 2024, both the US and Macao were each 50% of total EBITDA.